mecfa | mecfa 5/27

MECFA Blog

International Study Reports COVID-19 Outcomes in People With Cystic Fibrosis

Today the Cystic Fibrosis Foundation announced data from a collaborative, international effort to understand the impact of COVID-19 on...

Case Report Cites IDPN as Nutritional Tool in CF Patients with Kidney Disease

Delivering nutrients through dialysis could help people with co-occurring cystic fibrosis (CF) and kidney disease meet their nutritional...

Protein Called TAS2R38 Linked to Respiratory Tract Complications in CF

Problems with a protein called TAS2R38 are linked to a greater risk of severe sinonasal disease and Pseudomonas aeruginosa lung...

Staphylococcus Aureus in CF Airways Change With Age, Antibiotic Use, Study Says

Different types of Staphylococcus aureus can be found persistently in the airways of cystic fibrosis (CF) patients, but this bacteria...

Planned CHOICES Trial in Rare CF Mutations Given Regulatory Support

Proteostasis Therapeutics reported receiving scientific advice for its CHOICES clinical trial program, which is to test its personalized...

Simulations show how to make gene therapy more effective

Visualisation of a lipoplex entrapped inside an endosome. The DNA (yellow/pink rods) can only escape upon fusion of the lipoplex (red)...

Breaking the Diagnosis of Cystic Fibrosis to Parents: A process not a one-off event

2019 Royal Society of Medicine Cystic Fibrosis Symposium Breaking the Diagnosis of Cystic Fibrosis to Parents: A process not a one-off...

Coronavirus update: More considered vulnerable - full list of who should stay at home

CORONAVIRUS can be dangerous for the most vulnerable members of society. As time goes on, more health conditions - that increase a...

Arrowhead Pharmaceuticals files for regulatory clearance to begin phase 1/2a study of ARO-ENaC for t

rrowhead Pharmaceuticals has filed an application for clearance to begin a Phase 1/2a clinical trial of ARO-ENaC, the company’s...

McGill spinoff Laurent Pharmaceuticals to begin clinical trial on COVID-19 treatment

Company to run a Phase 2 clinical study with LAU-7b, a pro-resolving drug with potential antiviral properties against coronavirus Junji...

Disease Duration, Flare-ups Affect Mental Health of Non-CF Bronchiectasis Patients, Study Finds

VERTEX’S CF BLOCKBUSTER TRIKAFTA EFFECTIVE IN KIDS 6 TO 11 YEARS OF AGE

A case for improved carrier screening

Vertex to Seek Expanded FDA Approval for Trikafta After Positive Child Safety Data

Vertex’s Kaftrio approved for use in Europe and made accessible on the NHS

Age May Affect Outcomes in Lung Transplant Recipients With Cystic Fibrosis

CFF Funding Will Further ContraFect’s Research Into Alternative for Antibiotics

The search for molecular glue in targeted disease control

Vest Therapy Lowers Risk of Hospitalization in Non-CF Bronchiectasis, Study Says

Harvard is working with Boston hospitals to test existing cystic fibrosis drug to help coronavirus p